SCHEMBL1328523

SCHEMBL1328523

CCc1cccc(CC)c1-c1cc(OC)c(COc2cc(F)ccc2F)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 4/20 0.40
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
TGFBR1 P36897 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
CDK2 P24941 2/20 0.37
CDK9 P50750 2/20 0.37
ATP4A P20648 1/20 0.37
ATP4B P51164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PKM P14618 1/20 0.35
PARP14 Q460N5 1/20 0.35
PARP10 Q53GL7 1/20 0.35
MAP4K1 Q92918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1328404 0.91 ALDH1A1 (0.50) C5AR1ALDH1A1MEN1POLBHPGD
SCHEMBL1328504 0.90 KDM4E (0.42) C5AR1ALDH1A1MEN1HPGDKMT2A
SCHEMBL1327417 0.88 ATP4A (0.45) C5AR1ALDH1A1MEN1POLBHPGD
SCHEMBL1328913 0.87 ALDH1A1 (0.40) C5AR1ALDH1A1MEN1POLBHPGD
SCHEMBL1329221 0.87 C5AR1 (0.42) C5AR1ALDH1A1TGFBR1HDAC3HDAC1
SCHEMBL1328668 0.84 TGFBR1 (0.46) C5AR1ALDH1A1MEN1POLBHPGD
SCHEMBL1327858 0.83 MRGPRX4 (0.41) C5AR1HPGDTGFBR1SMN1; SMN2ADRA1D
SCHEMBL1329473 0.82 RECQL (0.43) C5AR1ADRA1D
SCHEMBL1330224 0.81 ABCB1 (0.44) C5AR1
SCHEMBL1329229 0.81 C5AR1 (0.44) C5AR1ALDH1A1MEN1POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342115-B2 Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology NEUROGEN CORPORATION (US) 2008-03-11 US claimed
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES HUTCHINSON ALAN J (US) 2011-11-17 US disclosed
US-7863454-B2 3-substituted-6-aryl pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2011-01-04 US disclosed
US-20090176980-A1 3-Substituted-6-Aryl Pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2009-07-09 US disclosed
US-7342115-B2 Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology NEUROGEN CORPORATION (US) 2008-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES C3AR1, C5AR1, C5AR2 C5AR1 2/4885ALDH1A1 1966/4885MEN1 3563/4885
US-20090176980-A1 3-Substituted-6-Aryl Pyridines C3AR1, C5AR1, C5AR2 C5AR1 2/4885ALDH1A1 1966/4885MEN1 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.